Document:

<PAGE>

                                                                   Exhibit 10(a)

                            THE LAMSON & SESSIONS CO.
            FIFTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT

     This Fifth Amendment to the Amended and Restated Credit Agreement (herein,
the "Amendment") is entered into as of July 29, 2003, among The Lamson &
Sessions Co., an Ohio corporation (the "Borrower"), the Guarantors party hereto,
the Lenders party hereto, and Harris Trust and Savings Bank, as Administrative
Agent for the Lenders.

                             PRELIMINARY STATEMENTS

     A. The Borrower, the Guarantors, the Lenders and the Administrative Agent
are parties to an Amended and Restated Credit Agreement dated as of December 15,
2000 (the Amended and Restated Credit Agreement, as the same has been amended
prior to the date hereof, being referred to herein as the "Credit Agreement").
All capitalized terms used herein without definition shall have the same
meanings herein as such terms have in the Credit Agreement.

     B. The Borrower and the Lenders have agreed to add an Excess Cash Flow
prepayment provision, amend certain financial covenants and related definitions,
and amend certain other provisions of the Credit Agreement, in each case under
the terms and conditions set forth in this Amendment.

     NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

SECTION 1. AMENDMENTS.

     Subject to the satisfaction of the conditions precedent set forth in
Section 2 below, the Credit Agreement shall be and hereby is amended as follows:

     1.1. Clause (iv) of Section 1.10(b) of the Credit Agreement (Prepayment;
Mandatory) shall be renumbered clause (v), and a new clause (iv) shall be
inserted into Section 1.10(b) of the Credit Agreement between clause (iii) and
amended clause (v) of the Credit Agreement which shall read as follows:

          (iv) On April 15th of each year, beginning April 15, 2004, the
     Borrower shall prepay the Term Loans by an amount equal to 50% of Excess
     Cash Flow of Borrower and its Subsidiaries for the most recently completed
     fiscal year of the Borrower.

<PAGE>

     1.2. Section 5.1 of the Credit Agreement (Definitions) shall be amended by
adding the following definition of Excess Cash Flow in appropriate alphabetical
order which read as follows:

          "Excess Cash Flow" means, with respect to any period, the amount (if
     any) by which (a) EBITDA (but determined for such purposes without giving
     effect to any extraordinary gains or losses) during such period exceeds (b)
     the sum of (i) Interest Expense payable in cash during such period, plus
     (ii) federal, state and local income taxes payable in cash during such
     period, plus (iii) the aggregate amount of payments of the Term Loans
     required to be made by the Borrower and its Subsidiaries during such period
     in respect of all principal on all Indebtedness of Borrowed Money (whether
     at maturity, as a result of mandatory sinking fund redemption, mandatory
     prepayment, acceleration or otherwise, but excluding payments made under
     the Revolving Credit and excluding mandatory prepayments of the Term Loans
     required to be made in respect of Excess Cash Flow under Section 1.9(b)
     hereof), plus (iv) the aggregate amount of Capital Expenditures made by the
     Borrower and its Subsidiaries during such period to the extent permitted by
     this Agreement and not financed with proceeds of Indebtedness for Borrowed
     Money, plus (iv) cash payments made during such period with respect to the
     Borrower's and its Subsidiaries' Plans and retiree medical plan expenses.

     1.3. The definition of "EBITDA" appearing in Section 5.1 of the Credit
Agreement (Definitions) shall be amended and restated in its entirety to read as
follows:

          "EBITDA" means, with respect to any period, Net Income for such period
     plus (A) all amounts deducted in arriving at such Net Income in respect of
     (a) Interest Expense, plus (b) federal, state, local, and foreign income
     taxes for such period, plus (c) amounts properly charged for depreciation
     of fixed assets and amortization of intangible assets during such period,
     plus (d) any charges to Net Income during such period which are non-cash,
     non-recurring expenses arising from the rationalization of the Borrower's
     facilities, product lines or personnel, up to a maximum amount equal to 10%
     of Net Worth at the end of such period, plus (e) any charges to Net Income
     during such period (up to $15,000,000 in the aggregate during the term of
     this Agreement, including any such charges accrued prior to the Effective
     Date) associated with the Intermatic Litigation, plus (f) any non-cash
     expenses incurred with respect to its Plans during such period, plus (g)
     any cash expenses incurred with respect to its Plans during such period up
     to a maximum amount of $500,000, plus (h) any cash or non-cash expenses
     incurred with respect to its retiree medical plans

                                      -2-

<PAGE>

     during such period up to a maximum amount of $500,000, plus (i) for the
     fiscal quarter ending September 30, 2003, one-time amendment fees up to
     $328,000 in the aggregate payable hereunder, minus (B) the sum of any
     recapture, recoveries, or other credits to Net Income during such period
     associated with respect to (a) the Intermatic Litigation, (b) its Plans,
     and (c) its retiree medical plans. In the event that any non-cash charge is
     excluded from the computation of EBITDA for a given period pursuant to
     clause (d) above but the circumstances giving rise to such charge have a
     cash impact in a subsequent period which would have reduced EBITDA but for
     the charge in the prior period, such impact shall be taken into account in
     computing EBITDA in the period when such impact occurs.

     1.4. Section 8.22 of the Credit Agreement (Total Funded Debt/EBITDA Ratio)
shall be amended and restated in its entirety to read as follows:

          Section 8.22. Total Funded Debt/EBITDA Ratio. The Borrower shall not,
     as of the last day of each fiscal quarter of the Borrower specified below,
     permit the Total Funded Debt/EBITDA Ratio to be more than:

                                                       TOTAL FUNDED
                                                     DEBT/EBITDA RATIO
     FISCAL QUARTER ENDING ON OR ABOUT:           SHALL NOT BE MORE THAN:

               June 30, 2003                            3.75 to 1.0
             September 30, 2003                         3.75 to 1.0
             December 31, 2003                          3.75 to 1.0
               March 31, 2004                           3.75 to 1.0
               June 30, 2004                            3.25 to 1.0
             September 30, 2004                         3.25 to 1.0
     December 31, 2004, and each fiscal                 2.75 to 1.0
         quarter ending thereafter

     1.5. Section 8.23 of the Credit Agreement (Interest Coverage Ratio) shall
be amended and restated in its entirety to read as follows:

          Section 8.23. Interest Coverage Ratio. The Borrower shall not, as of
     the last day of each fiscal quarter of the Borrower specified below, permit
     the ratio of (a) EBITDA for the four fiscal quarters of the Borrower then
     ended to (b) Interest Expense for the same four fiscal quarters then ended
     to be less than:

                                      -3-

<PAGE>

                                               INTEREST COVERAGE RATIO SHALL
     FISCAL QUARTER ENDING ON OR ABOUT:               NOT BE LESS THAN:

               June 30, 2003                            3.00 to 1.0
            September 30, 2003                          3.00 to 1.0
            December 31, 2003                           3.00 to 1.0
               March 31, 2004                           3.00 to 1.0
               June 30, 2004                            3.50 to 1.0
            September 30, 2004                          3.50 to 1.0
     December 31, 2004, and each fiscal                 4.00 to 1.0
         quarter ending thereafter

     1.6. Section 8.27 of the Credit Agreement (Minimum EBITDA) shall be amended
and restated in its entirety to read as follows:

          Section 8.27. Minimum EBITDA. As of the last day of each fiscal
     quarter of the Borrower specified below, the Borrower shall not permit
     EBITDA for the four fiscal quarters of the Borrower then ended to be less
     than:

                                                  EBITDA FOR FOUR FISCAL
                                               QUARTERS THEN ENDED SHALL NOT
     FISCAL QUARTER ENDING ON OR ABOUT:                 BE LESS THAN

               June 30, 2003                            $28,000,000
            September 30, 2003                          $28,000,000
             December 31, 2003                          $28,000,000
               March 31, 2004                           $28,000,000
               June 30, 2004                            $30,000,000
            September 30, 2004                          $30,000,000
     December 31, 2004, and each fiscal                 $32,000,000
         quarter ending thereafter

     1.7. Sections 8.29 and 8.30 of the Credit Agreement (Operating Review;
Financial Advisor) shall each be amended and restated in their entirety to read
as follows:

          Section 8.29. Intentionally deleted.

          Section 8.30. Intentionally deleted.

                                      -4-

<PAGE>

SECTION 2. CONDITIONS PRECEDENT.

     The effectiveness of this Amendment is subject to the satisfaction of all
of the following conditions precedent:

     2.1. The Borrower, the Administrative Agent, and the Required Lenders shall
have executed and delivered this Amendment.

     2.2. The Guarantors shall have executed and delivered to the Administrative
Agent their consent to this Amendment in the space provided below.

     2.3. The Borrower shall have paid to the Administrative Agent for
distribution to each Lender executing and delivering this Amendment on or before
July 29, 2003, a fee equal to 0.25% of the outstanding amount of each such
Lender's Revolving Credit Commitment and Term Loan.

     2.4. Legal matters incident to the execution and delivery of this Amendment
shall be satisfactory to the Administrative Agent and its counsel.

SECTION 3. REPRESENTATIONS.

     In order to induce the Lenders to execute and deliver this Amendment, the
Borrower hereby represents to the Lenders that as of the date hereof, and after
giving effect to the amendments provided for in this Amendment, (a) the
representations and warranties set forth in Section 6 of the Credit Agreement
are and shall be and remain true and correct (except that the representations
contained in Section 6.5 shall be deemed to refer to the most recent financial
statements of the Borrower delivered to the Lenders) and (b) the Borrower is in
compliance with the terms and conditions of the Credit Agreement and no Default
or Event of Default has occurred and is continuing under the Credit Agreement or
shall result after giving effect to this Amendment.

SECTION 4. MISCELLANEOUS.

     4.1. The Borrower and the Guarantors have heretofore or concurrently
herewith executed and delivered to the Lenders the Mortgages, the Security
Agreement, the Pledge Agreement, and certain other Collateral Documents. The
Borrower and, by signing below, the Guarantors, hereby acknowledge and agree
that the Liens created and provided for by the Collateral Documents continue to
secure, among other things, the Obligations arising under the Credit Agreement
as amended hereby; and the Collateral Documents and the rights and remedies of
the Lenders thereunder, the obligations of the Borrower and the Guarantors
thereunder, and the Liens created and provided for thereunder remain in full
force and effect and shall not be affected, impaired or discharged hereby.
Nothing herein contained shall in any manner affect or impair the priority of
the liens and security interests created and provided for by the Collateral
Documents as to the indebtedness which would be secured thereby prior to giving
effect to this Amendment.

                                      -5-

<PAGE>

     4.2. Except as specifically amended herein, the Credit Agreement shall
continue in full force and effect in accordance with its original terms.
Reference to this specific Amendment need not be made in the Credit Agreement,
the Notes, or any other instrument or document executed in connection therewith,
or in any certificate, letter or communication issued or made pursuant to or
with respect to the Credit Agreement, any reference in any of such items to the
Credit Agreement being sufficient to refer to the Credit Agreement as amended
hereby.

     4.3. The Borrower agrees to pay on demand all reasonable costs and expenses
incurred by the Administrative Agent in connection with the negotiation,
preparation, execution and delivery of this Amendment, including the reasonable
fees and expenses of counsel for the Administrative Agent.

     4.4. This Amendment may be executed in any number of counterparts, and by
the different parties on different counterpart signature pages, all of which
taken together shall constitute one and the same agreement. Any of the parties
hereto may execute this Amendment by signing any such counterpart and each of
such counterparts shall for all purposes be deemed to be an original. This
Amendment shall be governed by the internal laws of the State of Illinois.

                           [SIGNATURE PAGE TO FOLLOW]

                                      -6-

<PAGE>

     This Fifth Amendment to Amended and Restated Credit Agreement is entered
into as of the date and year first above written.

                           "BORROWER"

                           THE LAMSON & SESSIONS CO.

                           By /s/ James J. Abel
                              -----------------------------------------------
                              Name   James J. Abel
                                     ----------------------------------------
                              Title  Executive VP and Chief Financial Officer
                                     ----------------------------------------

                           "GUARANTORS"

                           CARLON CHIMES CO.

                           By /s/ James J. Abel
                              -----------------------------------------------
                              Name   James J. Abel
                                     ----------------------------------------
                              Title  Vice President, Secretary & Treasurer
                                     ----------------------------------------

                           DIMANGO PRODUCTS CORPORATION

                           By /s/ James J. Abel
                              -----------------------------------------------
                              Name   James J. Abel
                                     ----------------------------------------
                              Title  Secretary
                                     ----------------------------------------

                           PYRAMID INDUSTRIES II, INC.

                           By /s/ James J. Abel
                              -----------------------------------------------
                              Name   James J. Abel
                                     ----------------------------------------
                              Title  Vice President & Treasurer
                                     ----------------------------------------

                                      -7-

<PAGE>

                                 "LENDERS"

                                 HARRIS TRUST AND SAVINGS BANK, in its
                                    individual capacity as a Lender and as
                                    Administrative Agent

                                 By /s/ Michael J. Johnson
                                    --------------------------------------------
                                    Name   Michael J. Johnson
                                           -------------------------------------
                                    Title  Managing Director
                                           -------------------------------------

                                 BANK OF AMERICA, N.A.

                                 By /s/ Michael Staunton
                                    --------------------------------------------
                                    Name   Michael Staunton
                                           -------------------------------------
                                    Title  Senior Vice President
                                           -------------------------------------

                                 NATIONAL CITY BANK

                                 By /s/ Judith M. Kuclo
                                    --------------------------------------------
                                    Name   Judith M. Kuclo
                                           -------------------------------------
                                    Title  Senior Vice President
                                           -------------------------------------

                                 WOODSIDE CAPITAL PARTNERS II, LLC

                                 By: Woodside Capital Management, LLC,
                                     its duly authorized manager

                                 By /s/ Daphne J. Firth
                                    --------------------------------------------
                                    Name   Daphne J. Firth
                                           -------------------------------------
                                    Title  EVP
                                           -------------------------------------

                                 GENERAL ELECTRIC CAPITAL CORPORATION

                                 By /s/ James Desantis
                                    --------------------------------------------
                                    Name   James Desantis
                                           -------------------------------------
                                    Title  Duly Authorized Signatory
                                           -------------------------------------

                                 BANK ONE, N.A.

                                 By /s/ James M. Malz
                                    --------------------------------------------
                                    Name   James M. Malz
                                           -------------------------------------
                                    Title  First Vice President
                                           -------------------------------------

                                      -8-

<PAGE>

                                 THE HUNTINGTON NATIONAL BANK

                                 By /s/ Don W. Lambacher
                                    --------------------------------------------
                                    Name   Don W. Lambacher
                                           -------------------------------------
                                    Title  Senior Vice President
                                           -------------------------------------

                                 FIFTH THIRD BANK (NORTHEASTERN OHIO)

                                 By /s/ Roy C. Lanctot
                                    --------------------------------------------
                                    Name   Roy C. Lanctot
                                           -------------------------------------
                                    Title  Vice President
                                           -------------------------------------

                                 KEYBANK NATIONAL ASSOCIATION

                                 By /s/ Nadine M. Eames
                                    --------------------------------------------
                                    Name   Nadine M. Eames
                                           -------------------------------------
                                    Title  Vice President
                                           -------------------------------------

                                 LASALLE BANK NATIONAL ASSOCIATION

                                 By /s/ Robert M. Walker
                                    --------------------------------------------
                                    Name   Robert M. Walker
                                           -------------------------------------
                                    Title  VP
                                           -------------------------------------

                                      -9-<PAGE>
                                                                    Exhibit 10.1

                        [Mymetics Corporation letterhead]

                                  May 20, 2003

Prabhavathi B. Fernandes, Ph.D.
94 Gallup Road
Princeton, New Jersey 08540

Dear Dr. Fernandes:

         The purpose of this letter (the "AGREEMENT") is to appoint you to the
Mymetics Corporation Scientific Advisory Board (the "SAB") and to set forth our
understanding regarding your performance of certain additional activities for
Mymetics Corporation (the "COMPANY"). The terms and conditions of our
relationship are set forth below.

         1.       Engagement.

                  (a) Scientific Advisory Board Activities. You shall be
retained by the Company as a member of the SAB. As a member of the SAB, you
agree to provide (i) ongoing review and advice concerning the Company's
scientific strategy, policies, procedures and refinement of the Company's
research activities; (ii) serve as a reference to the Company's potential
partners; and (iii) assume and complete such other tasks from time to time as
are mutually agreeable to you and the Company. In addition, you agree to meet at
least two (2) times per year with one or more of the other members of the SAB at
a time and location set by the Company.

                  (b) Additional Activities. You have also agreed to provide
certain additional services upon the written request of the Company (the
"ADDITIONAL ACTIVITIES") including: (A) assisting the Company in identifying
potential strategic partnering opportunities in the area of therapeutic and
preventive treatment of AIDS and other retroviral diseases; (B) exploring
strategic partnering opportunities for the Company world-wide; and (C) in
limited circumstances, assisting in the negotiation of certain strategic
partnering arrangements approved by the Company.

         2.       Fees & Expenses.

                  (a) Stock Options. You shall be granted an option to purchase
up to 150,000 shares of the Company's Common Stock, $0.01 par value, pursuant to
the Company's 2001 Stock Option Plan on the effective date of this Agreement
(the "STOCK OPTION"). The exercise price for the Stock Option will be $0.12 per
share of Common Stock, which represents the average of the bid and ask price of
such shares as of May 1, 2003. The Stock Option shall vest immediately upon
the date of this Agreement and subject to the terms and conditions of the
Company's 2001 Stock Option Plan and the Stock Option Agreement, copies of which
have been forwarded to you under separate cover.

                  (b) Compensation for Additional Activities. In consideration
for providing the Additional Activities, the Company will pay you $1,000 per day
in cash, which amount shall

<PAGE>

be payable within 30 days of your submission of an invoice to the Company
detailing the Additional Activities performed.

                  (c) Expenses. The Company shall reimburse you for your
ordinary, necessary, and reasonable business expenses incurred on Company
business upon presentation of properly documented expense reports to the
Company's Chief Operating Officer, including the your reasonable expenses
incurred in attending the annual Interscience Conference on Antimicrobial Agents
and Chemotherapy. It is also agreed that you shall be entitled to subscribe to
certain publications annually; provided, however, that the annual fees for such
subscriptions shall not exceed $400 in the aggregate.

         3.       Term. The initial term of this Agreement (the "TERM") shall be
one year from the date hereof; provided, however, that your SAB membership may
be terminated by the Company at any time (during the initial term or any renewal
or extension thereof) by the giving of written notice to you. Notwithstanding
any other provisions of this Agreement, this Agreement shall terminate
automatically without notice at any time upon the occurrence of: (i) your death
or total and permanent disability; (ii) your material breach of this Agreement;
(iii) your conduct which becomes materially injurious to the Company; or (iv)
your continuing and unreasonable refusal to substantially perform your duties as
a member of the SAB.

         4.       Independent Contractor. You understand that you are an
independent contractor and not an employee of the Company. You have no authority
to obligate or bind the Company by contract or otherwise. You will not be
eligible for any employee benefits, and the Company will not make deductions
from your fees for taxes (except as otherwise required by applicable law or
regulation). Any taxes imposed on you due to activities performed hereunder will
be your sole responsibility. You agree to indemnify the Company against and hold
it harmless from all damages, costs, and expenses (including attorneys' fees)
which the Company may suffer or incur should it be held bound by any writing,
speech, action or inaction by you other than those consented to by the Company
in writing.

         5.       Confidential Information. You agree that you will not reveal
(or permit to be revealed) to a third party or use for your own benefit, either
during or after the term of this Agreement, without the prior written consent of
the Company, any Confidential Information (defined below) pertaining to the
business of the Company, its stockholders, subsidiaries or other affiliates
(collectively, "AFFILIATES") including but not limited to information about
customers, suppliers, employees, financial condition, operations, procedures,
know-how, production, distribution, experiments, patents, or other trade secrets
obtained while working with the Company or its Affiliates except for information
clearly established to be in the public record. For purposes of this Agreement,
"Confidential Information" is all information related to any aspect of the
business of the Company which is either information not known by actual or
potential competitors of the Company or is proprietary information of the
Company, whether of a technical nature or otherwise. Confidential Information
includes, without limitation, any inventions, disclosures, processes, systems,
methods, formulae, devices, patents, patent applications, trademarks,
intellectual properties, instruments, materials, products, patterns,
compilations, programs, techniques, sequences, designs, research or development
activities and plans, specifications, computer programs, source codes, mask
works, costs of production, prices or other financial data, volume of sales,
promotional methods, marketing plans, lists of names

<PAGE>

or classes of customers or personnel, lists of suppliers, business plans,
business opportunities, or financial statements.

         6.       Prior Contracts; Assignment of Inventions. Except as disclosed
in writing to the Company, (a) there are no other contracts to assign Inventions
(defined below) that are now in existence between you and any other person or
entity, and (b) no employments, consultancies or undertakings which would
restrict or impair your performance of this Agreement. "Inventions" mean any and
all inventions, ideas, designs, circuits, schematics, formulas, algorithms,
trade secrets, works of authorship, mask works, developments, methods,
processes, techniques, improvements, documents, software, graphics, media
productions, related know how and other data (whether or not patentable or
copyrightable), made, conceived, developed or reduced to practice or which will
be made, conceived, developed or reduced to practice by you, alone or in
combination with others, either on behalf of the Company under this Agreement,
or with the use of or as a result of access to Confidential Information,
including but not limited to any derivative work which constitutes an
improvement or modification to any tangible form of Confidential Information,
such as any formula, design, drawing, or any other product that embodies
Confidential Information. Any and all Inventions shall be the property of the
Company, and any Inventions which are made by you in performance of you duties
under this Agreement, to the maximum extent permitted by law, shall be "works
made for hire." You hereby assign and agree to assign to the Company or its
designee, without further consideration, your entire right, title, and interest
in and to all Inventions, including all rights to obtain, register, perfect, and
enforce patents, copyrights, mask work rights, and other intellectual property
protection for Inventions made in the HIV and FIV area fusion inhibitor and the
gp36 or gp41-derived vaccine areas.

         7.       Release. The Company and those acting on its behalf shall have
the right, with your permission, to make a public announcement of your
appointment and continued service on the SAB and to use, reuse, publish and
republish photographic portraits or pictures of you in connection with your
name, professional background, experience and position as a member of the SAB.

         8.       Noncompetition. You acknowledge the highly competitive nature
of the Company's business and that the Company's business is global and not tied
to a specific country or territory. You agree that during the Term of this
Agreement and for a period of one year thereafter, you will not, directly or
indirectly, as a consultant, employee, agent, director, or in any other
individual or representative capacity, engage or participate in providing
services which require the use or disclosure of Confidential Information of the
Company specifically related to HIV and FIV infusion inhibitors and gp36 or
gp41-derived vaccines and diagnostic products for the benefit of any actual or
potential competitor of the Company.

         9.       Arbitration. Any controversy or claim arising out of, or
relating to, this Agreement or the breach of this Agreement will be settled by
arbitration by, and in accordance with the applicable Commercial Arbitration
Rules of the American Arbitration Association and judgment upon the award
rendered by the arbitrator(s) may be entered in any court having jurisdiction.
The arbitrator(s) will have the right to assess, against a party or among the
parties, as the arbitrator(s) deem reasonable, (a) administrative fees of the
American Arbitration Association, (b) compensation, if any, to the arbitrator(s)
and (c) attorneys' fees incurred by a party.

<PAGE>

         10.      Injunctive Relief; Consent to Jurisdiction. You acknowledges
and agree that damages will not be an adequate remedy in the event of a breach
of any of you obligations under this Agreement. You therefore agree that the
Company shall be entitled (without limitation of any other rights or remedies
otherwise available to the Company and without the necessity of posting a bond)
to obtain an injunction from any court of competent jurisdiction prohibiting the
continuance or recurrence of any breach of this Agreement. You hereby agree to
submits to the jurisdiction and venue of the courts of the Commonwealth of
Pennsylvania for purposes of any such action.

         11.      Miscellaneous. The invalidity or unenforceability of any
provision of this Agreement shall in no way affect the validity or
enforceability of any other provision. This Agreement embodies the entire
agreement between the parties hereto and supersedes any and all prior or
contemporaneous, oral or written understandings, negotiations, or communications
on behalf of such parties. This Agreement may be executed in several
counterparts, each of which shall be deemed original, but all of which together
shall constitute one and the same instrument. The waiver by either party of any
breach or violation of any provision of this Agreement shall not operate or be
construed as a waiver of any subsequent breach or violation hereof. This
Agreement is executed in and shall be governed by and construed in accordance
with the laws of the Commonwealth of Pennsylvania. This Agreement shall be
changed, waived, discharged, or terminated only by written agreement of both
parties hereto. This Agreement shall inure to the benefit of the Company, its
successors and assigns.

         Please indicate your acceptance of the foregoing by signing and
returning one copy of this Agreement to the undersigned.

MYMETICS CORPORATION

By:  /s/ Michael K. Allio
     -------------------------------------
Name:  Michael K. Allio
Title:  Chairman

Accepted and agreed:

/s/ Prabhavathi B. Fernandes
------------------------------------------
Prabhavathi B. Fernandes, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]